Table 2.
Summary of biomarkers worthy of further development in gastrointestinal tumors
|
Classification
|
Biomarkers
|
Tumor type
|
Response to ICI
|
Ref.
|
| Tumor-genome biomarkers | POLE-mutation | Endometrial carcinoma | Pos | [93] |
| Neoantigen | Pulmonary adenocarcinoma | Pos | [94] | |
| Liquid-biopsy biomarkers | LDH | Melanoma | Neg | [99] |
| NLR | Advanced solid tumors | Neg | [100] | |
| Epigenetic | TET1-mutation | Multiple tumor types | Pos | [105] |
| miRNA | Non-small-cell lung cancer | Pos | [107] | |
| Patient characteristic | Gender | NA | Male: Pos; Female: Neg | [81,82] |
| Age | NA | Controversial1 | [84,115] | |
| Intestinal microbiota | NA | Pos/Neg | [85-87] |
Age as a marker remains controversial, and there are conflicting cases of relevant data.
POLE: Polymerase gene epsilon; LDH: Lactate dehydrogenase; NLR: Neutrophil-to-lymphocyte ratio; miRNA: Micro RNA; Pos positive: Neg negative; NA: Not applicable; ICI: Immune checkpoint inhibitor.